← Leaderboards
Carol K Conrad
Stanford University
$255,285
Attributed
$255,285
Total exposure
8
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $215K · FY2005–08$250K$187.5K$125K$62.5K$0
'05
'06
'07
'08
Funding mix
By agency
FDA$200,994 · 1
NIH$54,291 · 7
By mechanism
R01$200,994 · 1
M01$54,291 · 7
Top collaborators
No co-investigators on record.
Most similar at Stanford University
Same institution · by research overlap
- Krisa P Van Meurs$5,801,137
- Kari C. Nadeau$30,132,783
- Gideon Lack$3,214,542
- Dale T Umetsu$13,091,949
- Elizabeth Direnzo$2,115,155
Others in their field
Top investigators on “Cystic Fibrosis”
- John F Engelhardt · University Of Iowa$42,933,706
- Michael R Knowles · University Of North Carolina Chapel Hill$30,250,682
- David A Stoltz · University Of Iowa$25,455,359
- Joseph Zabner · University Of Iowa$25,382,103
- Paul B McCray · University Of Iowa$25,146,293
- Richard C Boucher · University Of North Carolina Chapel Hill$24,890,955
Research focus
Cystic FibrosisGrantFundingComputer Retrieval Of Information On Scientific Projects DatabaseResearch PersonnelSourceRandomizedResourcesInstitutionUnited States National Institutes Of HealthNebulizerClinical TrialsClinical ResearchDoseBreathingPharmaceutical PreparationsSafetyMaleAge-YearsLabelPersonsAdultForced Expiratory Volume FunctionHereditary Disease
Grant awards (8)
CLINICAL TRIAL: ALTU- 135 TREATMENT IN PATIENTS WITH CF-RELATED EXOCRINE PANCREA$2,389
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: SAFETY OF TOBRAMYCIN INHALATION POWDER COMPARED TO TOBI IN CYST$1,365
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: PARI EFLOW? ELECTRONIC NEBULIZER TO STABLE CYSTIC FIBROSIS PATIE$910
M01 · FY2008 · RR · contact PI
PHASE 2 & 3 TRIALS OF HIGH-DOSE ORAL N-ACETYLCYSTEINE IN CYSTIC FIBROSIS$200,994
R01 · FY2007 · FD · contact PI
TOBRAMYCIN INHALATION POWDER COMPARED TO TOBI IN CYSTIC FIBROSIS SUBJECTS$14,044
M01 · FY2007 · RR · contact PI
ORAL THERACLEC-TOTAL IN CYSTIC FIBROSIS SUBJECTS$11,565
M01 · FY2006 · RR · contact PI
ORAL THERACLEC-TOTAL IN CYSTIC FIBROSIS SUBJECTS$23,722
M01 · FY2005 · RR
A Phase I Trial Comparing Safety, Serum Pharmacokinetics and Delivery Time of...$296
M01 · FY2004 · RR